Pre-treatment Hemoglobin Levels are Important for Bladder Carcinoma Patients with Extravesical Extension undergoing Definitive Radiotherapy

Simple item page
dc.authorwosidKaplan, Mustafa/D-4977-2014
dc.contributor.authorYurut-Caloglu, Vuslat
dc.contributor.authorCaloglu, Murat
dc.contributor.authorKaplan, Mustafa
dc.contributor.authorInci, Osman
dc.date.accessioned2024-06-12T10:51:39Z
dc.date.available2024-06-12T10:51:39Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To evaluate prognostic factors affecting local control (LC), distant metastases-free survival (DMFS) and overall survival (OS) in bladder carcinoma patients undergoing extravesical extension. Patients and Methods: We retrospectively reviewed the charts of 61 consecutive patients with T3 or T4 bladder carcinoma, treated with definitive radiotherapy from 1999 through 2007. Results: Median age was 69 years and follow-up was 29 months. The LC rate was 33% at 4 years and was increased in patients with a Hb >= 12 g/dl (p=0.003) or a LDH<180 U/L (p=0.021) and in those who received concurrent chemotherapy (p=0.022) on univariate analysis. DMFS was affected by anemia (Hb<12 g/dl) (p=0.039), the absence of chemotherapy (p=0.034) and the presence of newlydiagnosed disease (p=0.01). The OS rate was 19% at 4 years. Non-pure transitional cell carcinoma histological type (p=0.024), anemia (p=0.004), elevated LDH (p=0.003), and newly diagnosed disease (p=0.011) were poor prognostic factors on univariate analyses for OS. Anemia was the only negative prognostic factor for LC (p=0.03), DMFS (p=0.002) and OS (p<0.0001) on multivariate analysis. Conclusion: Pre-treatment Hb level is the most important prognostic factor in patients treated with definitive radiotherapy, so that anemia may act as a surrogate biological marker for aggressive disease.en_US
dc.identifier.endpage1157en_US
dc.identifier.issn1513-7368
dc.identifier.issue6en_US
dc.identifier.pmid20192602en_US
dc.identifier.startpage1151en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18440
dc.identifier.volume10en_US
dc.identifier.wosWOS:000277237600036en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal Of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnemiaen_US
dc.subjectBladder Canceren_US
dc.subjectPrognostic Factoren_US
dc.subjectChemotherapy/Radiotherapyen_US
dc.subjectTurkeyen_US
dc.subjectTransitional-Cell-Carcinomaen_US
dc.subjectExternal-Beam Radiotherapyen_US
dc.subjectRadical Cystectomyen_US
dc.subjectUrinary-Bladderen_US
dc.subjectLocal-Controlen_US
dc.subjectProgressive Tumorsen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectCanceren_US
dc.subjectTherapyen_US
dc.subjectSurvivalen_US
dc.titlePre-treatment Hemoglobin Levels are Important for Bladder Carcinoma Patients with Extravesical Extension undergoing Definitive Radiotherapyen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize